Table 1 Characteristics of ALS patients and controls.
From: Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS
ALS patients (n = 40) | Control subjects (n = 45) | p-value | |
|---|---|---|---|
Mean +/− SD or percentage | Mean +/− SD or percentage | ||
Gender (% female) | 42.50 | 51.10 | 0.51 |
Age at sample collection | 66.12 +/− 12.10 | 60.58 +/− 14.01 | 0.06 |
Age at onset (years) | 64.67 +/− 12.17 | ||
BMI (kg/m2) | |||
at diagnosis | 24.52 +/− 3.82 | 25.31 +/− 3.20 | 0.21 |
at 12 months | 25.36 +/− 3.67 | ||
Weight loss at diagnosis (%) | 4.09 +/− 7.30 | ||
Diagnosis delay (months) | 12.52 + /−9.90 | ||
Site at onset (%) | |||
Spinal | 64.1 | ||
Bulbar | 30.8 | ||
Respiratory | 5.10 | ||
ALSFRS-r score | |||
at diagnosis | 40.18 +/− 5.25 | ||
at 12 months | 32.78 +/− 6.63 | ||
FVC (%) | |||
at diagnosis | 91.72 +/− 26.40 | ||
at 12 months | 80.34 +/− 22.16 | ||
Disease duration (months) | 33.62 +/− 18.40 | ||
